AU2005217696B2 - Method of evaluating the therapeutic potential of a vaccine for mucosal administration - Google Patents

Method of evaluating the therapeutic potential of a vaccine for mucosal administration Download PDF

Info

Publication number
AU2005217696B2
AU2005217696B2 AU2005217696A AU2005217696A AU2005217696B2 AU 2005217696 B2 AU2005217696 B2 AU 2005217696B2 AU 2005217696 A AU2005217696 A AU 2005217696A AU 2005217696 A AU2005217696 A AU 2005217696A AU 2005217696 B2 AU2005217696 B2 AU 2005217696B2
Authority
AU
Australia
Prior art keywords
weeks
level
solid phase
ige
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005217696A
Other languages
English (en)
Other versions
AU2005217696A1 (en
Inventor
Hans-Henrik Ipsen
Henrik Hugo Jacobi
Lise Lund Maerkedahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK Abello AS
Original Assignee
ALK Abello AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALK Abello AS filed Critical ALK Abello AS
Publication of AU2005217696A1 publication Critical patent/AU2005217696A1/en
Application granted granted Critical
Publication of AU2005217696B2 publication Critical patent/AU2005217696B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AU2005217696A 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration Ceased AU2005217696B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US54845404P 2004-02-26 2004-02-26
DKPA200400310 2004-02-26
DKPA200400310 2004-02-26
US60/548,454 2004-02-26
US55909504P 2004-04-02 2004-04-02
US60/559,095 2004-04-02
PCT/DK2005/000123 WO2005083385A2 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Publications (2)

Publication Number Publication Date
AU2005217696A1 AU2005217696A1 (en) 2005-09-09
AU2005217696B2 true AU2005217696B2 (en) 2008-02-14

Family

ID=34915878

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005217696A Ceased AU2005217696B2 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Country Status (8)

Country Link
EP (1) EP1718974A2 (pt)
JP (1) JP2007524096A (pt)
AU (1) AU2005217696B2 (pt)
BR (1) BRPI0508078A (pt)
CA (1) CA2556557A1 (pt)
IL (1) IL177703A0 (pt)
RU (1) RU2006134031A (pt)
WO (1) WO2005083385A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005217696B2 (en) * 2004-02-26 2008-02-14 Alk-Abello A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration
DK1974745T3 (da) 2007-03-28 2011-11-28 Alk Abello As Anvendelse af en adjuvansholdig allergivaccineformulering til subkutan administration
AU2008231722B2 (en) * 2007-03-28 2013-09-12 Alk-Abello A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
JP7062291B2 (ja) 2016-05-13 2022-05-16 応用酵素医学研究所株式会社 アレルギー発症リスクを予測するためのデータを収集する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021031A1 (en) * 1991-05-10 1992-11-26 Alain De Weck PROCEDURE FOR DETECTING AND PREPARING ANTI-IgE AUTOANTIBODIES AND USE OF THESE ANTIBODIES AS ACTIVE AGENTS IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS
US7888458B1 (en) * 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
CA2335615C (en) * 1998-06-24 2010-08-10 Alk-Abello A/S Method of detecting an antibody in a liquid sample
AU1960100A (en) * 1999-01-06 2000-07-24 Mcmaster University Method of preventing immune and hypersensitivity reactions
SE0004892D0 (sv) * 2000-12-29 2000-12-29 Pharmacia Diagnostics Ab Group 2 allergen specific IgE-Fabs and use thereof
GB0215710D0 (en) * 2002-07-05 2002-08-14 Isis Innovation Diagnostic method
UA62780A (en) * 2003-05-22 2003-12-15 Univ Oo Bohomolets Nat Medical Method for estimating efficiency of vaccination against diphtheria in children with allergic diathesis
AU2005217696B2 (en) * 2004-02-26 2008-02-14 Alk-Abello A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Also Published As

Publication number Publication date
CA2556557A1 (en) 2005-09-09
WO2005083385A2 (en) 2005-09-09
JP2007524096A (ja) 2007-08-23
IL177703A0 (en) 2006-12-31
BRPI0508078A (pt) 2007-07-17
EP1718974A2 (en) 2006-11-08
WO2005083385A3 (en) 2005-11-17
AU2005217696A1 (en) 2005-09-09
RU2006134031A (ru) 2008-04-10

Similar Documents

Publication Publication Date Title
AU2005304107B2 (en) Method of preventive treatment of allergy by mucosal administration of an allergy vaccine
AU2010200798B2 (en) An allergen dosage form
AU2006310881B2 (en) Use of a liquid allergy vaccine formulation for oromucosal administration
US20060002962A1 (en) Method of treating allergy and infection by eliciting an IGA antibody response
AU2005217696B2 (en) Method of evaluating the therapeutic potential of a vaccine for mucosal administration
US7887821B2 (en) Process for producing an allergen extract
EP1793853B1 (en) Liquid allergy vaccine formulation for oromucosal administration
US20060171968A1 (en) Method of preventive treatment of allergy by oromucosal administration of an allergy vaccine
EP1834648B1 (en) Process for producing an allergen extract
US20050202030A1 (en) Method of evaluating the therapeutic potential of a vaccine for mucosal administration
ES2344915T3 (es) Procedimiento de tratamiento preventivo de alergia por administracion mucosal de una vacuna de alergia.
MXPA06009737A (es) Metodo para evaluar el potencial terapeutico de una vacuna de administracion por la mucosa
RU2372074C2 (ru) Лекарственная форма, содержащая аллерген
ES2399914T3 (es) Uso de una formulación líquida de vacuna contra la alergia para administración oromucosa
ZA200702413B (en) Liquid allergy vaccine formulation for oromucosal administration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired